Weekly Research Analysts’ Ratings Changes for Solventum (SOLV)
Solventum (NYSE: SOLV) saw multiple analyst rating and target changes. Wedbush initiated coverage with an “outperform” rating and $94 target (5/15/26). UBS downgraded to “neutral” with $50 target (5/14/26) and previously cut its target to $78 (5/6/26). Other firms adjusted targets and ratings on 5/6/26, including Stifel ($90, buy), KeyCorp ($93, overweight), Wells Fargo ($70, equal weight), and BTIG ($89, buy). Director Amy Mcbride Wendell bought 1,475 shares at $68.03 (3/10/26).
How this was made
The 30-second read
Why it matters
The dominant trading signal is the concentration of target cuts and downgrades (notably UBS’s shift to neutral and target to $50), which can weigh on sentiment and risk appetite for SOLV until new company-specific catalysts emerge.
Market read
For traders, the key takeaway is sell-side sentiment skewing negative due to UBS and other target reductions, with mixed offsets from other firms.
What to watch
The article doesn’t include earnings, guidance, or company-specific catalysts; insider buying by a director (March 10) could be a supportive counter-signal that isn’t captured by rating changes.
Background
This is a weekly compilation of analyst rating and price-target changes for Solventum, plus a disclosed director share purchase.
Ticker impact
Solventum (SOLV) saw multiple analyst rating/target changes, including UBS downgrades to neutral and target cuts to $50, plus other firms’ target revisions.
Bias toward downside/volatility in the near term as the most recent UBS downgrade and large target reset ($50) can dominate flows, with potential mean-reversion if higher-target buyers (e.g., Wedbush/BTIG) attract dip-buying.
The article is entirely about analyst actions (not fundamentals), but the directionality is skewed negative due to UBS downgrades and multiple target reductions around 5/6–5/14, which typically affects short-term positioning.
Market effects
Analyst target dispersion in healthcare/medical solutions can signal uncertainty around demand, margins, or execution, potentially affecting peer sentiment even without peer-specific news.
Primarily US-listed sentiment; analyst coverage changes can move domestic healthcare trading desks and ETFs holding SOLV.
Limited direct global impact; however, UBS’s involvement can matter for cross-Atlantic coverage and positioning.
Counterpoint
The presence of multiple “buy/overweight” calls with higher targets (Wedbush $94, BTIG $89, KeyCorp $93) suggests the sell-side reset may be more about valuation/assumptions than a fundamental break.
Key entities
- companySolventum
Healthcare company whose shares are subject to multiple analyst rating/target changes and a director insider purchase.
- analyst_firmUBS Group AG
Downgraded SOLV from buy to neutral and cut its price target to $50.
- analyst_firmWells Fargo & Company
Cut its SOLV price target from $83 to $70 and moved to equal weight.
- analyst_firmWedbush
Initiated/covered SOLV with an outperform rating and $94 target.
- analyst_firmBTIG Research
Reaffirmed a buy rating and set a $89 price target.
